In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
News|Podcasts|April 28, 2026
ACT Brief: AI Impact Faces Reality Check, Supply Chain Risks Intensify, and RWE Shapes Global Strategy
Author(s)Andy Studna, Senior Editor
In today’s ACT Brief, we highlight where AI is delivering real gains in protocol development, how geopolitical disruption is redefining supply chain resilience, and the growing global impact of real-world evidence in drug development.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In part four of his video
interview , Mark Freitas of Alvarez & Marsal offered a measured view of AI’s role in clinical trials, noting that while it is accelerating upstream protocol development, clear evidence linking it to faster approvals and patient impact remains limited. - A new
Q&A with Hal Green of Loftware highlights how geopolitical instability is pushing clinical supply chains from an efficiency focus to a resilience imperative. As global disruptions become the norm, fragmented data and disconnected systems are emerging as key points of failure, with sponsors now prioritizing real-time visibility, adaptability, and continuity to prevent cascading delays and protect trial integrity. - At Asembia's AXS26 Summit, Tommy Brammley of Cencora
discussed how expanding FDA support for real-world evidence is shaping global launch strategies. Building on the 21st Century Cures Act, regulators in the US and Europe are increasingly accepting RWE, though data quality and methodology remain critical to ensure submissions are fit for purpose and free from bias.
That’s all for today’s ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
Trending on Applied Clinical Trials Online
1
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
2
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
3
Beyond the Molecule: Why Radiopharmaceutical Trials Require a New Operating Model
4
Operation TrialBlazer Leveraging New and Anticipated US Policy Changes in Early Development
5